CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 1010-1016

  Geissinger, Eva ^a   Bonzheim, Irina ^b   Roth, Sabine ^a   Rosenwald, Andreas ^a   Müller Hermelink, Hans Konrad ^a   Rüdiger, Thomas ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c Staedtisches Klinikum Karlsruhe   (Germany)

Author keywords

Anaplastic large cell lymphoma; Angioimmunoblastic T cell lymphoma; CD52; Not otherwise specified; Peripheral T cell lymphoma

Indexed keywords

ALEMTUZUMAB; ANAPLASTIC LYMPHOMA KINASE; CD3 ANTIGEN; CD30 ANTIGEN; CD52 ANTIGEN; CD79A ANTIGEN; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTE SUBPOPULATION; PERIPHERAL T CELL LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR CELL;

ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD30; ANTIGENS, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOPROTEINS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;

EID: 68449102375     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902926981     Document Type: Article

References (37)

1. Rudiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140-149.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008.
3. Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: First results of a prospective multicenter study. Hematol J 2004;5:304-311.
4. Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
5. Morris JC, Waldmann TA, Janik JE. Receptor-directed therapy of T-cell leukemias and lymphomas. J Immunotoxicol 2008;5:235-248.
6. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-1538.
7. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990;35: 118-127.
8. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993;82: 807-812.
9. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995;7:69-77.
10. Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293(Part 3):633-640.
11. Treumann A, Lifely MR, Schneider P, Ferguson MA. Primary structure of CD52. J Biol Chem 1995;270:6088-6099.
12. Hederer RA, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000;12:505-516.
13. Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003;101:1422-1429.
14. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-327.
15. Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098-1104.
16. Xia MQ, Hale G, Waldmann H. Efficient complementmediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993;30:1089-1096.
17. Nuckel H, Frey UH, Roth A, Duhrsen U, Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibodydependent cellular cytotoxicity. Eur J Pharmacol 2005;514: 217-224.
18. Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 1989;73: 1431-1439.
19. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998;95: 427-436.
20. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99:3554-3561.
21. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997;15:1567-1574.
22. Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004;10:867-876.
23. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 41:77-87.
24. Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998;16:3257-3263.
25. Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006;33:S44-S52.
26. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
27. Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: A multicenter phase I/II study. Ann Hematol 2002;81:26-32.
28. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121-3127.
29. Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19(Suppl):S27-S32.
30. Chang ST, Lu CL, Chuang SS. CD52 expression in nonmycotic T- and NK/ T-cell lymphomas. Leuk Lymphoma 2007;48:117-121.
31. Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566-567.
32. Miles RR, Cairo MS, Satwani P, Zwick DL, LonesMA, Sposto R, et al. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: A children's oncology group report. Br J Haematol 2007;138:506-512.
33. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, et al. Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-7179.
34. Geissinger E, Bonzheim I, Krenacs L, Roth S, Strobel P, Ott G, et al. Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based Tcell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn 2005;7:455-464.
35. Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004;104:3358-3360.
36. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998;22:185-191.
37. Jiang L, Yuan CM, Hubacheck J, Janik JE, Wilson W, Morris JC, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol, 2009;145:173-179.